Efficacy of Topical Cyclosporine 0.05% in the Prevention of NCT00383396

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Details — Status: Completed

Study information
Verified date	February 2007
Source	Innovative Medical
Contact	n/a
Is FDA regulated	No
Health authority	United States: Institutional Review Board
Study type	Interventional

To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.

Recruitment information / eligibility
Status	Completed
Enrollment	0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender	Both
Age group	N/A and older
Eligibility	Inclusion Criteria: - pts with symptomatic pterygia unresponsive to palliative treatment.

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label

Drug:
• Topical Cyclosporine

Locations
Country	Name	City	State
United States	Dr. Schechter	Boynton Beach	Florida

Sponsors *(1)*
Lead Sponsor	Collaborator
Innovative Medical

United States,